Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2020.04.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing Black and White Patients in Treatment of Advanced Prostate Cancer and Survival in an Equal Access Health System.
J Racial Ethn Health Disparities
October 2024
Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences (USUHS), 6720A Rockledge Drive, Suite 310, Bethesda, MD, 20817, USA.
Background: Racial disparities in prostate cancer treatment and survival in the U.S. have been attributed to differences in access to care and medical insurance.
View Article and Find Full Text PDFGeneral Obesity and Prostate Cancer in Relation to Abdominal Obesity and Ethnic Groups: A US Population-Based Cross-Sectional Study.
Res Rep Urol
October 2024
Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Background: Research suggests inconsistent evidence regarding the association between general obesity and prostate cancer among men in the United States. This study aimed to examine whether the association between general obesity and prostate cancer is influenced by abdominal obesity and ethnic groups.
Methods: The study utilized data from the National Health and Nutrition Examination Survey (NHANES).
Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.
NPJ Precis Oncol
September 2024
Danish Cancer Institute, Copenhagen, Denmark.
We analyzed genomic data from the prostate cancer of African- and European American men to identify differences contributing to racial disparity of outcome. We also performed FISH-based studies of Chromodomain helicase DNA-binding protein 1 (CHD1) loss on prostate cancer tissue microarrays. We created CHD1-deficient prostate cancer cell lines for genomic, drug sensitivity and functional homologous recombination (HR) activity analysis.
View Article and Find Full Text PDFTargeted Ablation Using Ultrasound-Guided Irreversible Electroporation of Index Tumors (TARGET Study): Prospective Development Study Evaluating Safety, Patient-Reported Outcomes, and Oncologic Efficacy.
Urol Pract
November 2024
Memorial Sloan Kettering Cancer Center, Department of Surgery, Urology Division, New York, New York.
Article Synopsis
- The study assessed the safety, patient-reported functional outcomes, and effectiveness of focal irreversible electroporation as a primary treatment for intermediate-risk prostate cancer.
- Between February 2015 and April 2017, 20 patients underwent this treatment, with results indicating no significant deterioration in urinary or sexual function six months post-treatment.
- At the 12-month mark, a significant portion of patients (74%) had no clinically significant cancer, with a radical treatment-free survival rate of 79% at two years, suggesting that the treatment could be beneficial for selected patients.
Adrenal cyst presenting with clinical features of a pheochromocytoma.
Radiol Case Rep
September 2024
Uniformed Services University of Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA.
Benign adrenal cysts are relatively uncommon variants of all adrenal incidentalomas. When identified, most benign adrenal cysts are asymptomatic, which differentiates them from other functional adrenal lesions. There are various types of adrenal cysts, although the most common being an endothelial cyst.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!